Shire CEO Angus Russell On The Value Proposition For Drugs
Executive Summary
Since 2008, Shire PLC 's market cap has nearly doubled ($8.3 billion to $16 billion) and its employee count has grown from 1,600 to roughly 4,300. Analysts say the U.K. company is on track to deliver its revenue guidance of 15% compound annual growth rate (CAGR) through 2015 – far above the expected anemic performance of most pharmaceutical companies.
You may also be interested in...
On A Revenue Roll, Shire Takes Specialist Tactics To “Primary Care” Markets
Shire targets specialist segments of vast primary care populations, with focus on areas of unmet need.
As Pharma Falters, Shire Specialist Model Hits Sweet Spot
With product sales growth that most big pharmas can only dream of, Shire's specialist model is working.
Rare Disease Research: Where Compassion Meets Commerce
The advent of a new set of potential acquirers has heightened venture capital's interest in rare diseases, resulting in the creation of a new cohort of drug developers that are using cutting edge technologies to treat and in some cases cure grave illnesses. In this issue, we profile Afraxis, bluebird bio, Edimer Pharmaceuticals and Ultragenyx Pharmaceutical.